Heart-rate response to alpha2-adrenergic receptor antagonism by antipsychotics

被引:4
作者
Kim, David D. [1 ]
Lang, Donna J. [2 ]
Warburton, Darren E. R. [3 ]
Woodward, Melissa L. [2 ]
White, Randall F. [4 ]
Barr, Alasdair M. [1 ]
Honer, William G. [4 ]
Procyshyn, Ric M. [4 ]
机构
[1] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC, Canada
[2] Univ British Columbia, Dept Radiol, Vancouver, BC, Canada
[3] Univ British Columbia, Cardiovasc Physiol & Rehabil Lab, Phys Act Promot & Chron Dis Prevent Unit, Vancouver, BC, Canada
[4] Univ British Columbia, Dept Psychiat, Room A3-111,938 West 28th Ave, Vancouver, BC V5Z 4H4, Canada
基金
加拿大健康研究院; 加拿大创新基金会;
关键词
Antipsychotics; Alpha(2)-adrenergic receptors; Heart rate; Schizophrenia; NERVOUS-SYSTEM; FAILURE; BINDING; DRUGS;
D O I
10.1007/s10286-017-0444-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To explore the relationship between antipsychotic-associated antagonism of alpha(2)-adrenergic receptors and resting heart rate in individuals with schizophrenia. Thirty-one inpatients treated with antipsychotics were included in this exploratory analysis. Antipsychotic doses were converted to haloperidol equivalents for alpha(2)-adrenergic receptor antagonism. Resting heart rate was measured with the patient in the seated upright posture. After controlling for confounding variables, the relationship between alpha(2)-adrenergic receptor antagonism and resting heart rate demonstrated a positive linear effect (P = 0.002) as well as a nonlinear effect that accounted for an additional 14% of the variability in resting heart rate (P = 0.005). The observed inverted-U relationship between alpha(2)-adrenergic receptor antagonism and resting heart rate can possibly be attributed to an altered response of beta(1)-adrenergic receptors to increased norepinephrine release. Further investigations are required to confirm this exploratory finding, taking into account additional variables that include other receptors which either directly or indirectly influence heart rate. NCT01392885.
引用
收藏
页码:407 / 410
页数:4
相关论文
共 13 条
[1]   A systematic review of clozapine induced cardiomyopathy [J].
Alawami, Mohammed ;
Wasywich, Cara ;
Cicovic, Aleksandar ;
Kenedi, Christopher .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 176 (02) :315-320
[2]   The role of inhibitory G proteins and regulators of G protein signaling in the in vivo control of heart rate and predisposition to cardiac arrhythmias [J].
Ang, Richard ;
Opel, Aaisha ;
Tinker, Andrew .
FRONTIERS IN PHYSIOLOGY, 2012, 3
[3]  
[Anonymous], 2015, CLIN HDB PSYCHOTROPI
[4]   Alpha-adrenoceptor subtypes [J].
Calzada, BC ;
De Artiñano, AA .
PHARMACOLOGICAL RESEARCH, 2001, 44 (03) :195-208
[5]   Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study [J].
Chow, V. ;
Yeoh, T. ;
Ng, A. C. C. ;
Pasqualon, T. ;
Scott, E. ;
Plater, J. ;
Whitwell, B. ;
Hanzek, D. ;
Chung, T. ;
Thomas, L. ;
Celermajer, D. S. ;
Kritharides, L. .
OPEN HEART, 2014, 1 (01)
[6]   Heart failure and tachycardia-induced cardiomyopathy [J].
Ellis E.R. ;
Josephson M.E. .
Current Heart Failure Reports, 2013, 10 (4) :296-306
[7]   EFFECT OF LONG-TERM TREATMENT WITH ATYPICAL NEUROLEPTIC DRUGS ON BETA-ADRENOCEPTOR BINDING IN RAT CEREBRAL-CORTEX AND MYOCARDIUM [J].
GROSS, G ;
SCHUMANN, HJ .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1982, 321 (04) :271-275
[8]   Alpha-1-Adrenergic Receptors in Heart Failure: The Adaptive Arm of the Cardiac Response to Chronic Catecholamine Stimulation [J].
Jensen, Brian C. ;
O'Connell, Timothy D. ;
Simpson, Paul C. .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2014, 63 (04) :291-301
[9]   Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system [J].
Leung, Joanne Y. T. ;
Barr, Alasdair M. ;
Procyshyn, Ric M. ;
Honer, William G. ;
Pang, Catherine C. Y. .
PHARMACOLOGY & THERAPEUTICS, 2012, 135 (02) :113-122
[10]   An Index of Relative Central α-Adrenergic Receptor Antagonism by Antipsychotic Medications [J].
Minzenberg, Michael J. ;
Yoon, Jong H. .
EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, 2011, 19 (01) :31-39